Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM Jr, Ellis C, Ibrahim N, Yan L. Tolcher AW, et al. Among authors: means powell j. Cancer Chemother Pharmacol. 2020 Apr;85(4):673-683. doi: 10.1007/s00280-020-04038-8. Epub 2020 Feb 15. Cancer Chemother Pharmacol. 2020. PMID: 32062691 Clinical Trial.
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).
Means-Powell JA, Mayer IA, Ismail-Khan R, Del Valle L, Tonetti D, Abramson VG, Sanders MS, Lush RM, Sorrentino C, Majumder S, Miele L. Means-Powell JA, et al. Clin Breast Cancer. 2022 Feb;22(2):103-114. doi: 10.1016/j.clbc.2021.10.013. Epub 2021 Oct 28. Clin Breast Cancer. 2022. PMID: 34903452 Free PMC article. Clinical Trial.
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Puzanov I, et al. Among authors: means powell ja. Invest New Drugs. 2015 Feb;33(1):159-68. doi: 10.1007/s10637-014-0167-5. Epub 2014 Oct 8. Invest New Drugs. 2015. PMID: 25294187 Free PMC article. Clinical Trial.
DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.
Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE. Li X, et al. Among authors: means powell j. Magn Reson Med. 2014 Apr;71(4):1592-602. doi: 10.1002/mrm.24782. Epub 2013 May 9. Magn Reson Med. 2014. PMID: 23661583 Free PMC article. Clinical Trial.
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA. Bauer JA, et al. Clin Cancer Res. 2010 Jan 15;16(2):681-90. doi: 10.1158/1078-0432.CCR-09-1091. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068102 Free PMC article.
Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE. Li X, et al. Among authors: means powell j. Invest Radiol. 2015 Apr;50(4):195-204. doi: 10.1097/RLI.0000000000000100. Invest Radiol. 2015. PMID: 25360603 Free PMC article.
A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer.
Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE. Li X, et al. Phys Med Biol. 2011 Sep 7;56(17):5753-69. doi: 10.1088/0031-9155/56/17/018. Epub 2011 Aug 12. Phys Med Biol. 2011. PMID: 21841212 Free PMC article.
Motion correction in diffusion-weighted MRI of the breast at 3T.
Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, Kelley MC, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE. Arlinghaus LR, et al. J Magn Reson Imaging. 2011 May;33(5):1063-70. doi: 10.1002/jmri.22562. J Magn Reson Imaging. 2011. PMID: 21509862 Free PMC article.
15 results